The expiry of Humira ® market exclusivity and the entry of adalimumab biosimilars in Europe: An overview of pricing and national policy measures

Conclusion: Even though originator adalimumab is the highest selling product in the world, few countries have implemented specific policies and practices for (biosimilar) adalimumab. Countries with biosimilars on the market seem to have competition lowering list or actual prices. Reported discounts varied widely between countries.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research